Adjunctive medical therapy

Clinical Trials in Heart Disease: A Companion to Braunwald's Heart Disease

Volumn , Issue , 2004, Pages 109-128

  Gornik, Heather L ^a   O'Gara, Patrick ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84904032106     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-0408-4.50015-9     Document Type: Chapter

References (102)

1. Drugs for the Heart 2001, W.B. Saunders Company, Philadelphia. ed. 5. L.H. Opie, B.J. Gersh (Eds.).
2. Yusuf S, Peto R, Lewis J, Collins R, Sleight P Beta blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis 1985, 27(5):335-371.
3. Held PH, Yusuf S Effects of beta-blockers and calcium channel blockers in acute myocardial infarction. Eur Heart J 1993, 14(F):18-25.
4. Freemantle N, Cleland J, Young P, et al. Beta Blockade after myocardial infarction: Systematic review and meta regression analysis. BMJ 1999, 318(7200):1730-1737.
5. Snow PJ Effect of propranolol in myocardial infarction. Lancet 1965, 2(7412):551-553.
6. Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet 1981, 2(8251):823-827.
7. The MIAMI Trial Research Group Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. Eur Heart J 1985, 6(3):199-226.
8. First International Study Group of Infarct Survival (ISIS-1) Collaborative Group Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986, 2(8498):57-66.
9. Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation 1991, 83(2):422-437.
10. The Norwegian Multicenter Group Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. New Engl J Med 1981, 304(14):801-807.
11. Beta-Blocker Heart Attack Trial Research Group A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982, 247(12):1707-1714.
12. Beta-Blocker Heart Attack Trial Research Group A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA 1983, 250(20):2814-2819.
13. Boissel JP, Leizorovicz A, Picolet H, et al. Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. Am J Cardiol 1990, 66(3):251-260.
14. Carvedilol Post-Infarct Survival Control in LV Dysfunction Investigators.Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction The CAPRICORN randomised trial. Lancet 2001, 357(9266):1385-1390.
15. Doughty RN, Rodgers A, Sharpe N, et al. Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. Eur Heart J 1997, 18(4):560-565.
16. Heidenreich PA, Lee TT, Massie BM Effect of beta-blockade on mortality in patients with heart failure: A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997, 30(1):27-34.
17. Swedberg K, Held P, Kjekshus J, et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). New Engl J Med 1992, 327(10):678-684.
18. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.GISSI-3 Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet 1994, 343(8906):1115-1122.
19. Chinese Cardiac Study Collaborative Group Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: Interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995, 345(8951):686-687.
20. Chinese Cardiac Study Collaborative Group (CCS-1) Oral captopril versus placebo among 14,962 patients with suspected acute myocardial infarction: A multicenter, randomized, double-blind, placebo controlled clinical trial. Chinese Med J 1997, 110(11):834-838.
21. Liu L Long-term mortality in patients with myocardial infarction: Impact of early treatment with captopril for 4 weeks. Chinese Med J 2001, 114(2):115-118.
22. Fourth International Study of Infarct Survival (ISIS-4) Collaborative Group ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995, 345(8951):669-685.
23. ACE Inhibitor Myocardial Infarction Collaborative Group Indications for ACE inhibitors in the early treatment of acute myocardial infarction: Systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation 1998, 97(22):2202-2212.
24. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. New Engl J Med 2000, 342(3):145-153.
25. Fox KM and The European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study).Lancet 2003, 362:782-788.
26. Pfeffer MA, Domanski M, Rosenberg Y, et al. PEACE Investigators: Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Am J Cardiol 1998, 82(3A):25H-30H.
27. Pfeffer MA, Domanski M, Verter J, et al. PEACE Investigators: The continuation of the Prevention of Events with Angiotensin-Converting Enzyme Inhibition (PEACE) Trial. Am Heart J 2001, 142(3):375-377.
28. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992, 327(10):669-677.
29. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993, 342(8875):821-828.
30. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. New Engl J Med 1995, 333(25):1670-1676.
31. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000, 355(9215):1575-1581.
32. Ambrosioni E, Borghi C, Magnani B The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. New Engl J Med 1995, 332(2):80-85.
33. Dickstein K, Kjekshus J Optimaal Steering Committee of the OPTIMAAL Study Group: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002, 360(9335):752-760.
34. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1999, 34(3):890-911.
35. Packer M, Kessler PD, Lee WH Calcium-channel blockade in the management of severe chronic congestive heart failure: A bridge too far. Circulation 1987, 75(6 Pt 2):V56-V64.
36. Littler WA, Sheridan DJ Placebo controlled trial of felodipine in patients with mild to moderate heart failure. UK Study Group. Br Heart J 1995, 73(5):428-433.
37. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. [comment]. New Engl J Med 1996, 335(15):1107-1114.
38. Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation 1997, 96(3):856-863.
39. Held PH, Yusuf S, Furberg CD Calcium channel blockers in acute myocardial infarction and unstable angina: An overview. BMJ 1989, 299(6709):1187-1192.
40. The Multicenter Diltiazem Postinfarction Trial Research Group The effect of diltiazem on mortality and reinfarction after myocardial infarction. New Engl J Med 1988, 319(7):385-392.
41. Furberg CD, Psaty BM, Meyer JV Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995, 92(5):1326-1331.
42. Gibson RS, Boden WE, Theroux P, et al. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial. New Engl J Med 1986, 315(7):423-429.
43. Theroux P, Gregoire J, Chin C, et al. Intravenous diltiazem in acute myocardial infarction. Diltiazem as adjunctive therapy to activase (DATA) trial. J Am Coll Cardiol 1998, 32(3):620-628.
44. Boden WE, van Gilst WH, Scheldewaert RG, et al. Diltiazem in acute myocardial infarction treated with thrombolytic agents: A randomised placebo-controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis (INTERCEPT). Lancet 2000, 355(9217):1751-1756.
45. The Danish Study Group on Verapamil in Myocardial Infarction Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II- DAVIT II). Am J Cardiol 1990, 66(10):779-785.
46. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction- summary article: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol 2002, 40(7):1366-1374.
47. Drummer C, Valta-Seufzer U, Karrenbrock B, et al. Comparison of anti-platelet properties of molsidomine, isosorbide-5-mononitrate and placebo in healthy volunteers. Eur Heart J 1991, 12(4):541-549.
48. Jugdutt BI, Warnica JW Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications. Effect of timing, dosage, and infarct location. Circulation 1988, 78(4):906-919.
49. Yusuf S, Collins R, MacMahon S, et al. Effect of intravenous nitrates on mortality in acute myocardial infarction: An overview of the randomised trials. Lancet 1988, 1(8594):1088-1092.
50. Lau J, Antman EM, Jimenez-Silva J, et al. Cumulative meta-analysis of therapeutic trials for myocardial infarction. New Engl J Med 1992, 327(4):248-254.
51. European Study of Prevention of Infarct with Molsidomine (ESPRIM) Group The ESPRIM trial: Short-term treatment of acute myocardial infarction with molsidomine. Lancet 1994, 344(8915):91-97.
52. Teo KK, Yusuf S, Collins R, et al. Effects of intravenous magnesium in suspected acute myocardial infarction: Overview of randomised trials. BMJ 1991, 303(6816):1499-1503.
53. Horner SM Efficacy of intravenous magnesium in acute myocardial infarction in reducing arrhythmias and mortality. Meta-analysis of magnesium in acute myocardial infarction. Circulation 1992, 86(3):774-779.
54. Woods KL, Fletcher S, Roffe C, et al. Intravenous magnesium sulphate in suspected acute myocardial infarction: Results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1992, 339(8809):1553-1558.
55. Woods KL, Fletcher S Long-term outcome after intravenous magnesium sulphate in suspected acute myocardial infarction: The second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1994, 343(8901):816-819.
56. Magnesium in Coronaries Trial (MAGIC) Investigators Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coro-naries (MAGIC) Trial: A randomised controlled trial. Lancet 2002, 360(9341):1189-1196.
57. Gianelly R, von der Groeben JO, Spivack AP, et al. Effect of lidocaine on ventricular arrhythmias in patients with coronary heart disease. New Engl J Med 1967, 277(23):1215-1219.
58. MacMahon S, Collins R, Peto R, et al. Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. JAMA 1988, 260(13):1910-1916.
59. Hine LK, Laird N, Hewitt P, et al. Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction. Arch Intern Med 1989, 149(12):2694-2698.
60. Teo KK, Yusuf S, Furberg CD Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 1993, 270(13):1589-1595.
61. Lie KI, Wellens HJ, van Capelle FJ, et al. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New Engl J Med 1974, 291(25):1324-1326.
62. Antman EM, Berlin JA Declining incidence of ventricular fibrillation in myocardial infarction. Implications for the prophylactic use of lidocaine. Circulation 1992, 86(3):764-773.
63. Sadowski ZP, Alexander JH, Skrabucha B, et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. Am Heart J 1999, 137(5):792-798.
64. International Mexiletine and Placebo Antiarrhythmic Coronary Trial (IMPACT) Research Group International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings. J Am Coll Cardiol 1984, 4(6):1148-1163.
65. Cardiac Arrhythmia Pilot Study (CAPS) Investigators. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction. Am J Cardiol 1988, 61(8):501-509.
66. Cardiac Arrhythmia Suppression Trial (CAST) Investigators.Preliminary report Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. New Engl J Med 1989, 321(6):406-412.
67. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. New Engl J Med 1991, 324(12):781-788.
68. Cardiac Arrhythmia Suppression Trial II (CAST) Investigators Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. New Engl J Med 1992, 327(4):227-233.
69. Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Lancet 1996, 348(9019):7-12.
70. Amiodarone Trials Meta-Analysis Investigators.Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure Meta-analysis of individual data from 6500 patients in randomised trials. Lancet 1997, 350(9089):1417-1424.
71. Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997, 349(9053):667-674.
72. Boutitie F, Boissel JP, Connolly SJ, et al. Amiodarone interaction with beta-blockers: Analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. Circulation 1999, 99(17):2268-2275.
73. Janse MJ, Malik M, Camm AJ, et al. Identification of post acute myocardial infarction patients with potential benefit from prophylactic treatment with amiodarone. A substudy of EMIAT (the European Myocardial Infarct Amiodarone Trial). Eur Heart J 1998, 19(1):85-95.
74. Cairns JA, Connolly SJ, Roberts R, et al. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997, 349(9053):675-682.
75. Elizari MV, Martinez JM, Belziti C, et al. Morbidity and mortality following early administration of amiodarone in acute myocardial infarction. GEMICA study investigators. Eur Heart J 2000, 21(3):198-205.
76. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. New Engl J Med 1999, 341(25):1882-1890.
77. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. New Engl J Med 1996, 335(26):1933-1940.
78. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. The Multicenter Automatic Defibrillator Implantation Trial 2 Investigators. New Engl J Med 2002, 346(12):877-883.
79. Jacoby RM, Nesto RW Acute myocardial infarction in the diabetic patient: Pathophysiology, clinical course and prognosis. J Am Coll Cardiol 1992, 20(3):736-744.
80. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): Effects on mortality at 1 year. J Am Coll Cardiol 1995, 26(1):57-65.
81. Malmberg K Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997, 314(7093):1512-1515.
82. Fath-Ordoubadi F, Beatt KJ Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: An overview of randomized placebo-controlled trials. Circulation 1997, 96(4):1152-1156.
83. Diaz R, Paolasso EA, Piegas LS, et al. Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group. Circulation 1998, 98(21):2227-2234.
84. Ceremuzynski L, Budaj A, Czepiel A, et al. Low-dose glucose-insulin-potassium is ineffective in acute myocardial infarction: Results of a randomized multicenter Pol-GIK trial. Cardiovasc Drugs Ther 1999, 13(3):191-200.
85. Dae MW, Gao DW, Sessler DI, et al. Effect of endovascular cooling on myocardial temperature, infarct size, and cardiac output in human-sized pigs. Am J Physiol Heart Circ Physiol 2002, 282(5):H1584-H1591.
86. The Hypothermia after Cardiac Arrest Study Group Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. New Engl J Med 2002, 346(8):549-556.
87. Bernard SA, Gray TW, Buist MD, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. New Engl J Med 2002, 346(8):557-563.
88. Dixon SR, Whitbourn RJ, Dae MW, et al. Induction of mild systemic hypothermia with endovascular cooling during primary percutaneous coronary intervention for acute myocardial infarction. J Am Coll Cardiol 2002, 40(11):1928-1934.
89. The Danish Study Group on Verapamil in Myocardial Infarction Verapamil in acute myocardial infarction. The Danish Study Group on Verapamil in Myocardial Infarction. Eur Heart J 1984, 5(7):516-528.
90. Rengo F, Carbonin P, Pahor M, et al. A controlled trial of verapamil in patients after acute myocardial infarction: Results of the calcium antagonist reinfarction Italian study (CRIS). Am J Cardiol 1996, 77(5):365-369.
91. Andre-Fouet X, Usdin JP, Gayet C, et al. Comparison of short-term efficacy of diltiazem and propranolol in unstable angina at rest-a randomized trial in 70 patients. Eur Heart J 1983, 4(10):691-698.
92. Theroux P, Taeymans Y, Morissette D, et al. A randomized study comparing propranolol and diltiazem in the treatment of unstable angina. J Am Coll Cardiol 1985, 5(3):717-722.
93. Gobel EJ, Hautvast RW, van Gilst WH, et al. Randomised, double-blind trial of intravenous diltiazem versus glyceryl trinitrate for unstable angina pectoris. Lancet 1995, 346(8991-8992):1653-1657.
94. Gobel EJ, van Gilst WH, de Kam PJ, et al. Long-term follow-up after early intervention with intravenous diltiazem or intravenous nitroglycerin for unstable angina pectoris. Eur Heart J 1998, 19(8):1208-1213.
95. Gerstenblith G, Ouyang P, Achuff SC, et al. Nifedipine in unstable angina: A double-blind, randomized trial. New Engl J Med 1982, 306(15):885-889.
96. Muller JE, Turi ZG, Pearle DL, et al. Nifedipine and conventional therapy for unstable angina pectoris: A randomized, double-blind comparison. Circulation 1984, 69(4):728-739.
97. Holland Interuniversity Nifedipine/Metoprolol Trial (HINT) Research Group Early treatment of unstable angina in the coronary care unit: A randomised, double blind, placebo controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both. Br Heart J 1986, 56(5):400-413.
98. Sirnes PA, Overskeid K, Pedersen TR, et al. Evolution of infarct size during the early use of nifedipine in patients with acute myocardial infarction: The Norwegian Nifedipine Multicenter Trial. Circulation 1984, 70(4):638-644.
99. Muller JE, Morrison J, Stone PH, et al. Nifedipine therapy for patients with threatened and acute myocardial infarction: A randomized, double-blind, placebo-controlled comparison. Circulation 1984, 69(4):740-747.
100. Wilcox RG, Hampton JR, Banks DC, et al. Trial of early nifedipine in acute myocardial infarction: The Trent study. BMJ (Clin Res Ed) 1986, 293(6556):1204-1208.
101. The Israeli SPRINT Study Group Secondary prevention reinfarction Israeli nifedipine trial (SPRINT). A randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J 1988, 9(4):354-364.
102. Goldbourt U, Behar S, Reicher-Reiss H, et al. Early administration of nifedipine in suspected acute myocardial infarction. The Secondary Prevention Reinfarction Israel Nifedipine Trial 2 Study. Arch Intern Med 1993, 153(3):345-353.